Jason Aboudi Mouabbi, M.D.

Peer-Reviewed Articles

1. Jason Mouabbi MD, Genevieve A Fasano MD, Helen M Johnson MD, Lin PhD HY, Kerollos Nashat Wanis MD, Susie X Sun MD, Anthony Lucci MD, Vicente Valero MD, Melissa Mitchell MD, Yu Shen PhD, Kelly K Hunt MD, Henry Kuerer MD. Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma. Ann Surg Oncol, 2026. e-Pub 2026.
2. Amin, LB, Lei, X, Middleton, LP, Hunt, KK, Mouabbi, JA, Giordano, SH, Chavez Mac Gregor, M. Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer. Journal of Clinical Oncology 44:605, 2026. e-Pub 2026.
3. Singareeka Raghavendra, A, Mouabbi, JA, Tarasov, A, Evdokimova, A, Smirnov, V, Rumyantsev, K, Barcenas, CH, Layman, RM, Savin, E, Lim, B, Pohlmann, PR, Damodaran, S, Hensley, M, Makani, N, Ogloblina, A, Fowler, N, Giordano, SH, Bagaev, A, Yam, C, Tripathy, D. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). Journal of Clinical Oncology 44:e13080-e13080, 2026. e-Pub 2026.
4. Mouabbi JA. MRD testing across the continuum of care. Clin Adv Hematol Oncol 24(4 Suppl 4):4-7, 2026. e-Pub 2026. PMID: 42283707.
5. Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol 24(4 Suppl 4):11-15, 2026. e-Pub 2026. PMID: 42283709.
6. Kaur, M, Quirarte, A, Vertido, A, Torosian, T, Li, TM, Mouabbi, JA, Mukhtar, RA. Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment 215(1), 2026. e-Pub 2026. PMID: 41307765.
7. Singareeka Raghavendra, A, Mouabbi, JA, Liu, D, Damodaran, S, Pasyar, S, Shen, Y, Barcenas, CH, Hunt, KK, Tripathy, D. Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer. Cancers 18(2), 2026. e-Pub 2026. PMID: 41595172.
8. Azhar, M, Mouabbi, JA, Soto, F, Su, A, Gonzalez, NV, Medina, KB, Madrigal, AL, Duran, CC, Reyna, CR, Chan, C, Shroff, G, Bassett Jr, R, Pasyar, S, Zhang, D, Shannon, VR, Altan, M, Mitchell, MP, Meric-Bernstam, F, Murthy, RK, Faiz, S, Bashoura, L, Lim, B, Sheshadri, A. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 41194091.
9. Singareeka Raghavendra, A, Mouabbi, JA, Liu, D, Pasyar, S, Damodaran, S, Shen, Y, Barcenas, CH, Tripathy, D. Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer. npj Breast Cancer 12(1), 2025. e-Pub 2025. PMID: 41663430.
10. Tarantino P, Mouabbi J, Rugo HS, Curigliano G, O’Shaughnessy JA, Janni W, Jhaveri K, Brufsky A, Hamilton E, O’Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, Graff SL. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a US Electronic Health Records database analysis. ESMO Open, 2025. PMID: 40516131.
11. Frank Vicini MD, Jason A Mouabbi MD, Chirag Shah MD, Karuna Mittal PhD, Sheila Weinmann PhD, Michael Leo PhD, G Bruce Mann MBBS PhD, Fredrik Warnberg MD PhD, Rachel Rabinovitch MD, Brian Czerniecki MD PhD, Icro Meattini MD, Atif Jalees Khan MD, Sachin Jhawar MD, Naamit Gerber MD, Shawna C Willey MD, Pat Borgen MD, Zahraa AlHilli MD, Megan Kruse MD, David Dabbs MD, Shivers PhD SC, Anna Daily PhD, Pat Whitworth MD, Michael Alvarado MD, Meena Moran MD, Hope Rugo MD, Joyce A O’Shaughnessy MD, Troy Bremer PhD. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk Ductal Carcinoma in Situ after Breast Conserving Surgery: The Impact of a 7-gene Biosignature based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates. Int J Radiat Oncol Biol Phys, 2025. e-Pub 2025. PMID: 40685017.
12. Middleton LP, Mouabbi JA, Perkins GH, Whitman GJ, Bevers TB, Yi M, Hunt KK. Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ. Breast Cancer Res Treat 213(2):225-235, 2025. PMID: 40637967.
13. Tarantino, P, Mouabbi, JA, Rugo, H, Curigliano, G, O'Shaughnessy, J, Janni, W, Jhaveri, KD, Brufsky, AM, Hamilton, E, O'Regan, R, Santarsiero, L, Akdere, M, Ye, F, Scotchmer, A, Graff, SL. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40516131.
14. Huynh VD, Mouabbi J, Kuerer HM, Wanis KN, Abdel-Salam HM, Gutierrez AM, Johnson HM, Lucci A, Hunt KK, Arun BK. Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma. Ann Surg Oncol 32(8):5477-5488, 2025. PMID: 40314901.
15. Raghavendra AS, Bassett R Jr, Damodaran S, Barcenas CH, Mouabbi JA, Layman R, Tripathy D. Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. JAMA Netw Open 8(4):e251888, 2025. e-Pub 2025. PMID: 40293750.
16. Gouda, MA, Gonugunta, A, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
17. Kuerer HM, Valero V, Smith BD, Krishnamurthy S, Diego EJ, Johnson HM, Lin H, Shen Y, Lucci A, Shaitelman SF, Mitchell MP, Boughey JC, Mouabbi JA, White RL, Hunt KK, Yang WT, Rauch GM, Exceptional Responders Study Group. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 11(5):529-534, 2025. PMID: 40152443.
18. Mouabbi JA, Qaio W, Shen Y, Raghavendra AS, Tripathy D, Layman RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist 29(3):213-218, 2024. e-Pub 2024. PMID: 38070191.
19. Mouabbi, JA, Meric-Bernstam, F, Nasrazadani, A, Nelson, BE, Salem, B, Kushnarev, V, Tkachuk, A, Sotova, M, Polyakova, M, Baranov, O, Turova, P, Chernyshov, K, Kotlov, N, Brown, JH, Clayton, P, Sarachakov, A, Postovalova, E, Bagaev, A, Tripathy, D, Layman, RM. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
20. Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250, 2023. e-Pub 2023. PMID: 37573674.
21. Mouabbi JA, Singareeka Raghavendra A, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open 6(5):e2313017, 2023. e-Pub 2023. PMID: 37166793.
22. Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer 8(1):131, 2022. e-Pub 2022. PMID: 36539444.
23. Mouabbi JA, Chand M, Asghar IA, Sakhi R, Ockner D, Dul CL, Hadid T, Aref A, Rimawi MF, Hoyos V. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med 10(14):4790-4795, 2021. e-Pub 2021. PMID: 34080777.
24. Chaar A, Mouabbi JA, Alrajjal A, Barawi M. Metastatic Testicular Choriocarcinoma: An Unusual Cause of Upper Gastrointestinal Bleed. Cureus 11(7):e5243, 2019. e-Pub 2019. PMID: 31565641.
25. Zein RK, Al-Faham Z, Mouabbi JA, Daher ER. An Uncommon Variant of an Uncommon Disease: A Caucasian Adolescent with Apical Hypertrophic Cardiomyopathy Diagnosed with Myocardial Perfusion Imaging. World J Nucl Med 16(3):251-254, 2017. e-Pub 2017. PMID: 28670188.
26. Frieder J, Mouabbi JA, Zein R, Hadid T. Autoimmune hemolytic anemia associated with trimethoprim-sulfamethoxazole use. Am J Health Syst Pharm 74(12):894-897, 2017. e-Pub 2017. PMID: 28596226.
27. Mouabbi JA, Zein R, Kafri Z, Al-Katib A, Hadid T. Thrombotic thrombocytopenic purpura presenting as acute coronary syndrome. Clin Case Rep 4(8):736-9, 2016. e-Pub 2016. PMID: 27525072.
28. Mouabbi JA, Agarwal N, El Kaderi B, Ansari A. Role for gene looping in intron-mediated enhancement of transcription. Proc Natl Acad Sci U S A 109(22):8505-10, 2012. e-Pub 2012. PMID: 22586116.

Invited Articles

1. Bidard F, Mouabbi JA, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, Curigliano G, Dawood S, Fasching PA, Gerratana L, Giordano A, Ignatiadis M, Iwata H, Janni W, Lim E, Kalinsky K, Ma CX, Mayer EL, Medford AJ, O’Shaughnessy J, Park YH, Pascual J, Razavi P, Sammons S, Sandoval JL, Sisca L, Tarantino P, Wander SA, Werutsky G, Turner NA. SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer. NPJ Breast Cancer 12(1), 2026. e-Pub 2026.
2. Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J, Moon DH, de Vries EGE. Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol. J Nucl Med 64(3):351-354, 2023. e-Pub 2023. PMID: 36863779.

Review Articles

1. Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol 24(4 Suppl 4):1-16, 2026. e-Pub 2026. PMID: 42283705.
2. Baelen K, Mouabbi J, Sawyer E, Cauwenberge J, Aftimos P, Covington MF, Maetens M, Zels G, Brisken C, Djerroudi L, Dresen R, Fitzpatrick A, Flaherty RL, Floris G, Freeney S, Hanker AB, Honey D, Isacke CM, Jankowitz RC, Jeselsohn R, Koorman T, Kuhl C, Linn S, Lord CJ, Malhaire C, Mukhtar R, Nader-Marta G, Natrajan R, Neven P, Oesterreich S, Sandoval JL, Schnitt SJ, Senkus E, Turner C, Vandecaveye V, Wildiers H, Vincent-Salomon A, Derksen PWB, Desmedt C. Clinical challenges and proposed solutions for patients with invasive lobular breast cancer. Ann Oncol, 2025. PMID: 40701440.
3. Batra H, Mouabbi JA, Ding Q, Sahin AA, Raso MG. Lobular Carcinoma of the Breast. Cancers (Basel) 15(22):5491, 2023. e-Pub 2023. PMID: 38001750.
4. Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193(2):253-264, 2022. e-Pub 2022. PMID: 35347549.
5. Mouabbi JA, Osborne CK, Schiff R, Rimawi MF. Management of hormone receptor-positive human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat 190(2):189-201, 2021. e-Pub 2021. PMID: 34515904.

Other Articles

1. Bidard, FC, Mouabbi, JA, Barrios, CH, Bianchini, G, Brufsky, AM, Chia, S, Cortes, J, Cristofanilli, M, Curigliano, G, Dawood, S, Fasching, PA, Gerratana, L, Giordano, A, Ignatiadis, M, Iwata, H, Janni, W, Lim, E, Kalinsky, K, Ma, CX, Mayer, E, Medford, AJ, O'Shaughnessy, J, Park, YH, Pascual, J, Razavi, P, Sammons, S, Sandoval, JL, Sisca, L, Tarantino, P, Wander, SA, Werutsky, G, Turner, NA SERENA-6 interpretation and clinical implications. npj Breast Cancer 12(1), 2026. PMID: 42259831.

Editorials

1. Mouabbi J. Second Oral SERD Shines in ER+ Breast Cancer. Cancer Discov 13(3):522, 2023. PMID: 36661374.

Abstracts

1. Mouabbi JA, Raghavendra AS, Adesoye T, Pasyar S, Bassett RL, Jr, Mukhtar RA, Valero V, Hassan AA, Nasrazadani A, Lim B, Ehlers RA, Jr, Checka C, Layman RM, Mac Gregor MC, Giordano SH, Litton JK, Meric-Bernstam F, Mark Kuerer AH. Distant recurrence–free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?. ASCO 2026, 2026. e-Pub 2026.
2. Mouabbi JA, Pohlmann PR, Layman RM, Bassett RL, Jr, Middleton LP, Lim B, Zaayman T, Nomie K, Barykin E, Evdokimova A, Mac Gregor MC, Litton JK, Giordano SH, Meric-Bernstam AF. IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC). ASCO 2026, 2026. e-Pub 2026.
3. Amin LB, Mouabbi JA, Lei X, Middleton LP, Hunt K, Giordano SH, Mac Gregor AMC. Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer. ASCO 2026, 2026. e-Pub 2026.
4. Raghavendra AS, Mouabbi JA, Tarasov A, Evdokimova A, Smirnov V, Rumyantsev K, Barcenas CH, Layman RM, Savin E, Lim B, Pohlmann PR, Damodaran S, Hensley M, Makani N, Ogloblina A, Fowler NH, Giordano SH, Bagaev A, Yam C, Tripathy AD. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). ASCO 2026, 2026. e-Pub 2026.
5. Sullivan M, Mouabbi JA, Lei X, Jackson I, Mac Gregor AMC. Chemotherapy (CT) use by Oncotype DX (O-Dx) recurrence score (RS) in hormone receptor–positive, HER2-negative (HR+/HER2-) invasive lobular carcinoma (ILC): A contemporary National Cancer Database (NCDB) analysis. ASCO 2026, 2026. e-Pub 2026.
6. Mouabbi JA, Ilheme A, Koenig K, Haymaker C, Hammell A, Suryawanshi S, Middleton L, Bassett R, Zaayman T, Geoffrey L, Pohlmann PR, Giordano SH, Litton JK, Meric-Bernstam F. Safety run-in of REPLOT: Phase II repotrectinib plus fulvestrant in HR+/HER2− metastatic invasive lobular carcinoma (mILC) after endocrine therapy (ET) and CDK4/6 inhibition. ESMO Breast Cancer 2026, 2026. e-Pub 2026.
7. Valero V, Mouabbi J, Pohlmann PR, Huang X, Qiao W, Alonzo HR, Murthy RK, Rauch GM, Adesoye T, Checka CM, Symmans WF, Grachev D, Alajajyan F, Nwosu-Iheme A, Hassan A, Patel MM, Giordano SH, Hunt K, Tripathy D, Meric-Bernstam F. A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study. AACR 2026, 2026. e-Pub 2026.
8. Mouabbi J, Pohlmann P, Layman R, Bassett R, Middleton L, Lim B, Zaayman T, Nomie K, Barykin E, Evdokimova A, Chavez-MacGregor M, Litton J, Giordano S, Meric-Bernstam F. IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC). AACR 2026, 2026. e-Pub 2026.
9. Kim N, Mouabbi J, Vertido A, Quirarte A, Batra-Sharma H, Abeles E, Moya J, Chien J, Mukhtar R. Eligibility for CDK4/6 inhibitor treatment in 861 patients with invasive lobular carcinoma of the breast: the importance of nodal staging for adjuvant therapy decisions. SABCS 2025, 2026. e-Pub 2026.
10. Taranto E, Mouabbi J, Fawn W, Desirae C, Walinsky E, Deluca S, Bayne L, Wileyto E, Shirali A, Robbins C, Abdou Y, Anampa J, Balic M, Canzoniero J, Chen N, Howard F, Huppert L, Kahn A, Mainor C, Nair V, Degeer T, Weidler J, McNicholas T, Serway C, Reischl J, Bates M, Monroe R, Rimm D, DeMichele A. Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066). SABCS 2025, 2026. e-Pub 2026.
11. Vertido A, Mouabbi J, Quirarte A, Chien J, Mukhtar R. Validation of the Modified Preoperative Endocrine Prognostic Index (mPEPI) in a single institution cohort of patients with invasive lobular carcinoma. SABCS 2025, 2026. e-Pub 2026.
12. Laurentiis M, Mouabbi J, Im S, Kruse M, Chia S, Brucker S, Villanueva C, Jerusalem G, Gao M, Sopher G, Wu J, Zarate J, Beck J. Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC). SABCS 2025, 2026. e-Pub 2026.
13. Ravani L, Mouabbi J, Bagheri Z, Kalinsky K, Burstein H, Bardia A, O’Regan R, Wander S. Progression-free Survival by Local Investigators vs. Blinded Independent Central Review in Hormone-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-analysis. SABCS 2025, 2026. e-Pub 2026.
14. Yam C, Radko A, Huo L, Akshara S, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas C, Bisen A, Brewster A, Buzdar A, Gregor M, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme A, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward W, Hunt K, Litton J, Valero V, Tripathy D, Rauch G, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. SABCS 2025, 2026. e-Pub 2026.
15. Mouabbi J, Raghavendra A, Pasyar S, Roland B, Mukhtar R, Giancarlo M, Wright M, Bisen A, Iheme A, Barcenas C, Valero V, Nasrazadani A, Lim B, Ramirez D, Hassan A, Kuerer H, Adesoye T, Paula P, Meric-Bernstam F, Giordano S, Litton J, Layman R. Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). SABCS 2025, 2026. e-Pub 2026.
16. Mouabbi J, pohlmann P, Lim B, Mukhtar R, Grachev D, Baranov B, Chalabyan C, Goncharova D, Turova P, Chernyshov K, Kushnarev V, Paradiso F, Litton J, Layman R, Meric-Bernstam F, Rodon J. Tumor-associated macrophage (TAMs) and cancer-associated fibroblasts (CAFs) profiles in invasive lobular carcinoma (ILC) vs no special type (NST). SABCS 2025, 2026. e-Pub 2026.
17. Mitchell-Daniels M, Axelrod J, Cushing T, Hutcheson L, Jochelson M, Joergensen G, Langdon T, Mouabbi J, Mukhtar R, Neilsen B, Paluch-Shimon S, Petitti L, Romer D. Invasive lobular breast cancer and surveillance: A patient experience survey study. SABCS 2025, 2026. e-Pub 2026.
18. POHLMANN P, Mouabbi J, Potter D, Chen N, Jahan N, Han H, Diamond J, Bhave M, Rampurwala M, Rayani S, Discacciati A, Eklund M, Chappel A, Delson A, LeStage B, Hendricks-Kretzer C, Venters S, Brown-Swigart L, Hirst G, Petricoin E, III, Borowsky A, Veer L, Asare S, Jafari S, Henderson P, Tripathy D, Rugo H, Nanda R, Stringer-Reasor E, Yee D, Meric-Bernstam F, Esserman L. Pre-ispy trial: a phase i/ib oncology platform program (pre-i-spy-p1). SABCS 2025, 2026. e-Pub 2026.
19. POHLMANN P, Mouabbi J, Chen N, Jahan N, Rampurwala M, Discacciati A, Eklund M, Chapple A, Hirst G, Venters S, Brown-Swigart L, Petricoin E, III, Borowsky A, Veer L, Delson A, Asare S, Jaffari S, Henderson P, Tripathy D, Esserman L, Rugo H, Nanda R, Stringer-Reasor E, Yee D, Meric-Bernstam F, Potter D. Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial. SABCS 2025, 2026. e-Pub 2026.
20. Chen Y, Mouabbi J, Shui A, Lee C, Vertido A, Kaur M, Moya J, Abeles E, Quirarte A, Prionas N, Mukhtar R. Comparing Utilization and Survival Outcomes of Post-mastectomy Radiation Therapy in Invasive Lobular versus Ductal Carcinoma: A National Cancer Database Analysis. SABCS 2025, 2026. e-Pub 2026.
21. Lin N, Mouabbi JA, Chien J, Ma CX, Abramson V, Potter DA, Sparano J, Khong HT, Chaves J, Tan A, Alemany CA, Sabanathan D, Loutfi R, Sun L, Shaw M, Vecchio D, Borges V. Palazestrant (OP-1250) plus ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced breast cancer (ABC). 2025 ESMO Congress, 2025. e-Pub 2025.
22. Mouabbi J, Nasrazadani A, Damodaran S, Kushnarev V, Goncharova D, Baranov O, Chernyshov K, Kust S, Kotlov N, Clayton P, Pohlmann P, Tripathy D, Meric-Bernstam F. Comprehensive Analysis of ADC Target Expression in Invasive Lobular Carcinoma. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
23. Borges V, Mouabbi JA, Chien J, Nunnery S, Ma CX, Bahadur S, Potter DA, Sabanathan D, Tan AR, Sun L, Shaw M, Vecchio D, Lin NU. A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
24. Tarantino P, Mouabbi JA, Rugo HS, Curigliano G, O’Shaughnessy J, Janni W, Jhaveri K, Brufsky A, Hamilton E, O’Regan R, Kim J, Santarsiero L, Akdere M, Ye F, Owusu H, Graff SL. Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
25. Mouabbi JA, Raghavendra AS, Pasyar S, Bassett RL, Jr, Nasrazadani A, Barcenas CH, Hassan AA, Tripathy D, Layman RM. MDA iLobulaRx: An Advanced Clinico-Patho-Therapeutic Tool for Risk Stratification in Early-Stage Invasive Lobular Carcinoma. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
26. Muanya E, Potter A, Waldvogel K, Raghavendra AS, Pasyar S, Bassett RL, Valero V, Tripathy D, Barcenas CH, Mouabbi JA. Outcomes of Metastatic Breast Cancer Patients Initiated on Inpatient Chemotherapy Due to Visceral Crisis. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
27. Gouda M, Mouabbi JA, Gonugunta A, Dumbrava E, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Tripathy D, Sahin A, Chen H, Meric-Bernstam F. HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
28. Yam C, Mouabbi JA, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, Rauch GM. Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC). 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
29. Middleton LP, Mouabbi JA, Perkins GH, Whitman GJ, Bevers TB, Yi M, Hunt K. Upgrade rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
30. Mouabbi JA, Sakr Y, Raghavendra AS, Adesoye T, Kuerer HM, Nasrazadani A, Hassan AA, Bisen A, Moscol G, Valero V, Barcenas CH, Tripathy D, Middleton LP, Layman RM, Pohlmann PR, Meric-Bernstam F. Outcomes of neoadjuvant endocrine therapy (NAET) versus neoadjuvant chemotherapy (NAC) in stage II-III invasive lobular carcinoma (ILC). 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
31. Mouabbi JA, Kushnarev V, Goncharova D, Baranov O, Chernyshov K, Kotlov N, Paradiso F, Hensley M, Layman RM, Tripathy D, Pohlmann PR, Meric-Bernstam F. Macroscale genomic alterations in histomolecular invasive lobular carcinoma compared to other breast cancer subtypes. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
32. Huynh VD, Mouabbi J, Kuerer HM, Wanis KN, Abdel-Salam HM, Gutierrez AM, Johnson HM, Lucci A, Hunt KK, Arun BK. Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes among 877 Patients with Invasive Lobular Carcinoma. Annual Meeting of the Society of Surgical Oncology, 2025. e-Pub 2025. PMID: 40314901.
33. Mouabbi JA, Sakr Y, Raghavendra A, Abualkhair OA, Barcenas CH, Damodaran S, Layman RM, Tripathy D, Pohlmann PR, Meric-Bernstam F. Real-world effectiveness of trastuzumab deruxtecan (T-DXd) in endocrine therapy (ET)-refractory metastatic invasive lobular carcinoma (mILC) with HER2-low wild type (HER2wt) versus HER2-low mutant (HER2m). 2025 ESMO Breast Cancer, 2025. e-Pub 2025.
34. Rugo HS, Mouabbi JA, Lu Y, Tarantino P, Brezden-Masley C, Gombos A, Bailleux C, Jacot W, Horsmans Y, Forns X, Akdere M, Ye F, Sopher G, Thomson B, Sammons S. Real-world (RW) analysis of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB). 2025 ESMO Breast Cancer, 2025. e-Pub 2025.
35. Mouabbi JA, Hammell A, Suryawanshi S, Middleton L, Bassett R, Zaayman T, Geoffrey L, Meric-Bernstam F. REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition. American Association of Cancer Research, 2025. e-Pub 2025.
36. Barrientos-Toro E, Mouabbi JA, Batra H, Renganayaki P, Rizvi YQ, Meric-Bersntam FF, Ding Q, Sahin A, Raso MG. Differential TROP2 immunohistochemical expression between pleomorphic and classic invasive lobular carcinoma of the breast. 2025 American Association for Cancer Research Annual Meeting, 2025. e-Pub 2025.
37. Lopez E, Nasrazadani A, Baranov O, Smirnov V, Love A, Paradiso F, Hensley M, Layman R, Mouabbi J, Yam C, Nelson B, Sadia S, Valero V, Stauder M, Woodward W, Lucci A, Sun S, Whitman G, Patel M, Le-Petross H, Lu Y, Marx A, Alexander A, Yajima C, Kai M, Villarreal L, Lopez H, Giordano S, Litton J, Bora L. Distinct Immune Landscapes in Inflammatory and Metaplastic Breast Cancer: Insights from Transcriptomic Profiling. SABCS 2025, 2025. e-Pub 2025.
38. AZHAR M, MOUABBI J, SOTO F, VAZQUEZ-GONZALEZ NA, AMBER SU, FAIZ SA, SHESHADRI A. Incidence and risk factors for pneumonitis due to trastuzumab deruxtecan in females with breast cancer. 2024 CHEST Annual Meeting, 2024. e-Pub 2024.
39. Gerber NK, Mittal K, Shah CS, Vicini FA, Mouabbi J, Whitworth PW, Willey S, Krystel-Whittemore M, Yates CC, Karanam B, Acs G, Pernicone E, Tempest M, Cox CE, Beard A, Czerniecki B, Dabbs D, Savala J, Wadsten C, Bremer T. A Novel Comprehensive Multi-Omic Biosignature to Assess Recurrence Risk and Adjuvant Therapy Benefit in Early-Stage Hormone-Positive Invasive Breast Cancer Patients. ASTRO Annual Meeting, 2024. e-Pub 2024.
40. Tarantino P, Mouabbi JA, Rugo HS, Curigliano G, O'Shaughnessy J, Janni W, Jhaveri K, Brufsky AM, Hamilton EP, ORegan R, Santarsiero EC, Sum E, Scotchmer A, Ye F, Graff S. Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis. 2024 ESMO Congress, 2024. e-Pub 2024.
41. Mouabbi JA, Meric-Bernstam F, Nasrazadani A, Nelson BE, Salem B, Kushnarev V, Tkachuk A, Sotova M, Polyakova M, Baranov O, Turova P, Chernyshov K, Kotlov N, Brown JH, Clayton P, Sarachakov A, Postovalova E, Bagaev A, Tripathy D, M Layman AR. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
42. Pohlmann PR, Potter DA, Chen N, Mouabbi JA, Rampurwala M, Rayani S, Tan AR, Leon-Ferre RA, Giridhar K, Boughey JC, Han HS, Kennedy LC, Walsh EM, Tripathy D, Jafari S, Eklund M, Nanda R, Meric-Bernstam F, Yee D, Esserman AL. PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
43. Borges VF, Mouabbi JA, Chien J, Nunnery S, Ma CX, Bahadur S, Chavez J, Potter DA, Sabanathan D, Tan AR, Sun L, Faltaos D, Tonda M, Lin NU. 212P A phase Ib/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. 2024 ESMO Breast Cancer Annual Congress 9, 2024. e-Pub 2024.
44. Mouabbi JA, Meric-Bernstam F., Bassett R, Tripathy D, Layman R. 224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is). 2024 ESMO Breast Cancer Annual Congress 9, 2024. e-Pub 2024.
45. Mouabbi J, Chernyshov K, Baranov O, Kushnarev V, Turova P, Butusova A, Menshikova S, Brown J, Kotlov N, Clayton P, Nomie K, Fowler N, Tripathy D. An integrated approach for comprehensive molecular and tumor microenvironment characterization of invasive lobular carcinoma. 2023 SABCS Annual Meeting 84(9), 2024. e-Pub 2024.
46. Valero V, Mouabbi J, Alonzo H, Pohlmann P, Lheme A, Hassan A, Murthy R, Huang X, Qiao W, Patel M, Rauch G, Checka C, Symmans W, Hunt K, Tripathy D, Meric-Bernstam F. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer. 2023 SABCS Annual Meeting 84(9), 2024. e-Pub 2024.
47. Mouabbi J, Pasyar S, Bassett R, Raghavendra AS, Hassan A, Layman R, Tripathy D. MDA iLobular Prognostic Tool: A Novel Approach for Risk Stratification in Invasive Lobular Carcinoma. 2023 SABCS Annual Meeting 84(9), 2024. e-Pub 2024.
48. Mouabbi JA. Innovative approaches at the diagnosis and treatment of invasive lobular carcinoma. 2023 SABCS Annual Meeting 84:9_supplement, 2024. e-Pub 2024.
49. Kuerer H, Mouabbi JA, Rauch G, Krishnamurthy S, Diego E, Yang W, Shen Y, Lin H, Lucci A, Moseley T, Ramirez D, Boughey J, Shaitelman S, White R, Hunt K, Mitchell M, Teshome M, Johnson H, Smith B, Valero V. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial 34:S280, 2023. e-Pub 2023.
50. Valero V, Mouabbi JA, Alonzo H, Nwosu Iheme A, Murthy R, Huang X, Qiao W, Patel M, Pohlmann PR, Rauch G, Checka C, Hunt K, Tripathy D, Meric-Bernstam F, Symmans F. Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC) 8(1), 2023. e-Pub 2023.
51. Mouabbi JA, Meric-Bernstam F, Khorkova S, Turova P, Kotlov N, Chernyshov K, Kushnarev V, Love A, Clayton P, Nomie K, Flower N, Tripathy D. Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas 41(16), 2023. e-Pub 2023.
52. Mouabbi JA, Meric-Bernstam F, Turova P, Chernyshov K, Kushnarev V, Kotlov N, Brown J, Clayton P, Nomie K, Flower N, Tripathy D, Damodaran S. Genomic characterization of the GATA3 mutational landscape in breast cancer 41(16), 2023. e-Pub 2023.
53. Mouabbi JA, Qiao W, Raghavendra AS, Shen Y, Tripathy D, Layman RM. Efficacy of single-agent chemotherapy in endocrine therapy-refractory metastatic invasive lobular carcinoma 8(1), 2023. e-Pub 2023.
54. Yam C, Mouabbi JA, Tripathy D. Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer 83(5), 2023. e-Pub 2023.
55. Mouabbi JA, Raghavendra AS, Bassett R, Hassan A, Tripathy D, Layman R. Abstract P5-02-30: Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression 83(5), 2023. e-Pub 2023.
56. Raghavendra AS, Mouabbi JA, Bassett R, Layman R, Tripathy D. Abstract P3-05-38: Biology and clinical course of lobular cancer in breast cancer (BC) 83(5), 2023. e-Pub 2023.
57. Raghavendra AS, Mouabbi JA, Liu D, Tripathy D. Abstract HER2-04: HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0 83(5), 2023. e-Pub 2023.
58. Mouabbi JA, Raghavendra AS, Christgen M, Hassan A, Hortobagyi G, Tripathy D, Layman R. P3-05-04: Absence of Lobular Carcinoma In Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma 83(5), 2023. e-Pub 2023.
59. Hutchenson L, Axelrod J, Camden A, Charlevoix D, Jochelson MS, Kruse ML, Lagdon T, Levine J, McKay C, Metzger O, Mitchell-Daniels M, Neilsen B, Mouabbi JA. Abstract P6-05-50: Lobular Breast Cancer Alliance Inc. Survey of Individuals with Metastatic Invasive Lobular Carcinoma 83(5), 2023. e-Pub 2023.
60. Mouabbi JA, Raghavendra AS, Bassett R, Hassan A, Tripathy D, Layman R. Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor 40(16), 2022. e-Pub 2022.
61. Mouabbi JA, Sako Zeyad, Abdalla A, Hadid T, Rimawi M. Abstract PS3-30: Peri-operative diagnostic accuracy of magnetic resonance imaging and ultrasonography in breast cancer: A meta-analysis 81(4), 2021. e-Pub 2021.
62. Mouabbi JA, Chand M, Sakhi R, Asghar I, Ockner D, Hadid T, Dul C, Rimawi M, Aref A. Abstract PS15-01: Radiation therapy improves survival in early-stage HER2-positive breast cancer with high-level of tumor infiltrating lymphocytes 81(4), 2021. e-Pub 2021.
63. Mouabbi JA, Malapati S, Abdalla A, Biedny A, Hayward D, Szpunar S, Hadid T, Berri R, Kafri Z. A new prognostic model for high-grade appendiceal mucinous neoplasms with peritoneal carcinomatosis 38(15), 2020. e-Pub 2020.
64. Mouabbi JA, Chand M, Sakhi R, Ockner D, Szpunar S, Dul C, Hadid T, Kafri Z, Aref A. Abstract P4-12-09: Improvement of survival with radiation therapy in early stage triple negative breast cancer patients with high level of tumor infiltrating lymphocytes 80(4), 2020. e-Pub 2020.
65. Malapati S, Mouabbi JA, Singh S, Kumar R, Abdalla A, Dul C, Hadid T. Abstract P2-08-04: Bilateral mastectomy in ductal carcinoma in situ: 10-year analysis of national inpatient sample database 80(4), 2020. e-Pub 2020.
66. Malapati S, Mouabbi JA, Singh S, Kumar R, Hadid T. Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive? 134:2353, 2019. e-Pub 2019.
67. Shiari A, Mouabbi JA, Zein R, Zalt M. Dyspnea Following Y-Silicon Stent Placement, 2019. e-Pub 2019.
68. Mouabbi JA, Uh E, Hadid T. Effectiveness of low-dose CT scan for lung cancer screening in the community setting 37(15), 2019. e-Pub 2019.
69. Malapati S, Mouabbi JA, Khan U, Kafri Z, Hadid T, Berri R. Single center experience: Management of metastatic appendiceal cancer with peritoneal carcinomatosis 37(15), 2019. e-Pub 2019.
70. Kafri Z, Mouabbi JA, Hadid T. Intravenous Iron for the Treatment of Steroid-Refractory Idiopathic Thrombocytopenic Purpura 132:3768, 2018. e-Pub 2018.
71. Mouabbi JA, Zein R, Szpunar S, Saravolatz L, Kafri Z, Hadid T. Neutrophils-to- Lymphocytes Ratio and Platelets-to-Lymphocytes Ratio as Predictive Markers of Deep Vein Thrombosis 152(4), 2017. e-Pub 2017.
72. Zein R, Mouabbi JA, Rezik M, Hadid T. Taxanes and Sjögrens Syndrome - A Fatal Combination: A Case Report 150(4), 2016. e-Pub 2016.
73. Ahmed Z, Mouabbi JA, Barawi M, Sheikh MA. A Very Rare Case of ‘Lyme-Induced Pancreatitis 111, 2016. e-Pub 2016.
74. Zein R, Mouabbi JA, Hadid T, Barawi M. Elevated Liver Enzymes Treated with Nephrectomy: A Case of Stauffers Syndrome 111:S965, 2016. e-Pub 2016.
75. Mouabbi JA, Zein R, Ahmed Z, Al-Nabhan G, Alrajjal A, Barawi M. Metastatic Testicular Choriocarcinoma Leading to Upper GI Bleed 111:S1086, 2016. e-Pub 2016.
76. Mouabbi JA, Zein R, Hadid T. A Rare Case of Imatinib-Induced Acute Respiratory Distress Syndrome Requiring Extracorporeal Membrane Oxygenation 150(4), 2016. e-Pub 2016.
77. Zein R, Mouabbi JA, Jalal S, Hadid T, Attallah A. An Exotic Treatment For An Exotic Disease: Plasmapheresis For The Treatment Of Non St-Segment Elevation Myocardial Infarction 67(13), 2016. e-Pub 2016.
78. Zein R, Mouabbi JA, Inany M, Hadid T, Lalonde T. Evolving Heart Block treated With a CHOP 134(1), 2016. e-Pub 2016.

Book Chapters

1. Mouabbi J, Kafri Z. Management of Sickle Cell Anemia. In: Management of Anemia: A Comprehensive Guide for Clinicians. 1. Springer, 219-236, 2018.

Books (edited and written)

1. Mouabbi JA. Invasive lobular cancer: Current evidence and clinical practice. Hospital Healthcare Europe, 2023.

Web Publications

1. Jackson I, Mouabbi J. Serial ESR1 Mutation Monitoring in First-Line Management of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer, 2026.
2. Mouabbi JA, Butaud M. Appropriate Monitoring and Multidisciplinary Coordination Can Help Avoid Serious Hyperglycemia for Patients with PI3K/AKT Alterations and HR+/HER2- Breast Cancer, 2026.
3. Mouabbi JA. The Evolution of Molecular Testing and Targeted Therapy in HR+/HER2– Breast Cancer, 2025.
4. Sakr Y, Mouabbi JA. Treatment Down the Line: Exploring Third-Line Options for ER-Positive, PIK3CA-Mutated Breast Cancer, 2025.
5. Mouabbi JA. Insights From SABCS 2023: Treatment Strategies for HR+/HER2- Breast Cancer, 2023.
6. Mouabbi JA. Clinical Challenges: The Emerging Identity of Lobular Breast Cancer — Navigating the similarities and differences of the "unseen" subtype of breast cancer, 2023.
7. Mouabbi JA. Medscape Drugs & Diseases: Breast Cancer Treatment Protocols, 2023.
8. Mouabbi JA. Navigating the Horizon: Anticipating Breakthroughs at SABCS 2023, 2020.